MATCH
Findings - Primary Endpoint
596 (15.7%) patients reached the primary endpoint in the group receiving ASA and clopidogrel compared with 636 (16.7%) in the clopidogrel alone group (relative risk reduction 6.4%, [95% CI –4.6 to 16.3]; absolute risk reduction 1% [-0.6 to 2.7]).
Primary Endpoint (ITT)
No significant RRR of clopidogrel + ASA compared to clopidogrel alone
